10-Q quarterly report · filed Nov 2, 2026

Syndax Pharmaceuticals Inc (SNDX) Q3 2026 10-Q Quarterly Report

Short answer

Syndax Pharmaceuticals Inc (SNDX) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $83M (up 81.6% year over year) with net income of −$49M.

Q3 2026 key financials · XBRL

Revenue
$83M
+81.6% YoY · +14.4% QoQ
Net income
−$49M
+18.6% YoY · −0.1% QoQ
Operating margin
-50.3%
EPS (diluted)
−$0.55
+20.3% YoY · +1.8% QoQ

Source: XBRL data from the Syndax Pharmaceuticals Inc (SNDX) Q3 2026 10-Q on SEC EDGAR. USD.

Syndax Pharmaceuticals Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $83.3M, up $37.4M YoY from $45.9M
  • Revuforj revenue $60.7M, up 90% YoY, strongest product performance
  • Niktimvo revenue $67.4M, up 47% YoY, collaboration revenue $22.6M
  • Operating loss $41.9M vs $57.4M YoY, operating margin -50.3% vs -125.2%
  • Cash used in operations $107.9M; financing provided $263.9M, including $250.0M convertible notes

Risk Factors

  • Newly added risk: $250.0M convertible notes issued in June 2026, creating conversion-related dilution exposure through 13,631,400 shares
  • Financial risk: $344.1M royalty financing liability with 13.8% Niktimvo sales participation and $822.5M payment cap
  • Regulatory risk: Revuforj sales milestone triggered a $10.0M September 2026 obligation under the Vitae license
  • Operational risk: Cost of product sales rose to $13.996M from $2.100M as commercial product volumes expanded
  • Market risk: Niktimvo revenue participation payments reduce cash generated from U.S. product sales

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Syndax Pharmaceuticals Inc quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.